Literature DB >> 18408762

Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.

N Goldin1, L Arzoine, A Heyfets, A Israelson, Z Zaslavsky, T Bravman, V Bronner, A Notcovich, V Shoshan-Barmatz, E Flescher.   

Abstract

Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor-the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC-activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfectants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408762     DOI: 10.1038/onc.2008.108

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

1.  Voltage dependent anion channel-1 (VDAC-1) as an anti-cancer target.

Authors:  Saroj P Mathupala; Peter L Pedersen
Journal:  Cancer Biol Ther       Date:  2010-06-21       Impact factor: 4.742

2.  Metabolic control of the cell cycle.

Authors:  Joanna Kalucka; Rindert Missiaen; Maria Georgiadou; Sandra Schoors; Christian Lange; Katrien De Bock; Mieke Dewerchin; Peter Carmeliet
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 3.  Mitochondrial ion channels as therapeutic targets.

Authors:  Pablo M Peixoto; Shin-Young Ryu; Kathleen W Kinnally
Journal:  FEBS Lett       Date:  2010-02-20       Impact factor: 4.124

Review 4.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

5.  Hacking hexokinase halts tumor growth.

Authors:  Yongjun Fan; Wei-Xing Zong
Journal:  Cancer Biol Ther       Date:  2008-06-30       Impact factor: 4.742

Review 6.  Pharmacological modulation of mitochondrial ion channels.

Authors:  Luigi Leanza; Vanessa Checchetto; Lucia Biasutto; Andrea Rossa; Roberto Costa; Magdalena Bachmann; Mario Zoratti; Ildiko Szabo
Journal:  Br J Pharmacol       Date:  2019-01-02       Impact factor: 8.739

7.  Methyl jasmonate ameliorates rotenone-induced motor deficits in rats through its neuroprotective activity and increased expression of tyrosine hydroxylase immunopositive cells.

Authors:  Akinyinka O Alabi; Abayomi M Ajayi; Benneth Ben-Azu; Osarume Omorobge; Solomon Umukoro
Journal:  Metab Brain Dis       Date:  2019-08-28       Impact factor: 3.584

8.  Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.

Authors:  Danya Ben-Hail; Racheli Begas-Shvartz; Moran Shalev; Anna Shteinfer-Kuzmine; Arie Gruzman; Simona Reina; Vito De Pinto; Varda Shoshan-Barmatz
Journal:  J Biol Chem       Date:  2016-10-13       Impact factor: 5.157

9.  Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.

Authors:  Steffen Klippel; Jana Jakubikova; Jake Delmore; Melissa Ooi; Douglas McMillin; Efstathios Kastritis; Jacob Laubach; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Br J Haematol       Date:  2012-09-13       Impact factor: 6.998

10.  PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells.

Authors:  Uri Elia; Eliezer Flescher
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.